Iron Deficiency Anemia Treatment Market (Drug Type: Ferrous Sulfate, Ferrous Gluconate, Ferrous Fumerate, Ferric Hydroxide, Sodium Ferric Gluconate, Iron Carbohydrates, and Others; Dosage Form: Tablets, Capsules, and Liquid; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2021-2027

The global Iron Deficiency Anemia Treatment market gathered revenue around USD 10.1 Billion in 2020 and market is set to grow USD 21.9 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 8.7% during the prediction period 2021 to 2027.

Iron Deficiency Anemia Treatment Market Size 2020 to 2027

Growth Factors:

The market  Iron deficiency is the most common cause of anemia globally. Rise in prevalence of chronic kidney diseases, increase in risk of hemodilution in pregnant women, and surge in iron deficiency in individuals are the major factors anticipated to drive the global iron deficiency anemia treatment market during the forecast period. North America held a major share of the global iron deficiency anemia treatment market in 2020, due to large population suffering from iron deficiency, higher awareness about iron deficiency anemia, and increase in focus on new product launches by industry players. The iron deficiency anemia treatment market in Asia Pacific is expected to expand at a high CAGR of 9.7% from 2021 to 2027 due to increase in the number of geriatric patients suffering from iron deficiency and chronic kidney diseases.

This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the Iron Deficiency Anemia Treatment market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global Iron Deficiency Anemia Treatment market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.

Report Coverage

Report Scope Details
Market Size USD 21.9 Billion by 2027
Growth Rate CAGR of 8.7% From 2021 to 2027
Base Year 2020
Forecast Period 2021 to 2027
Historic Data 2017 to 2020
Report coverage Growth Factors, Revenue Status, Competitive Landscape,  and Future Trends
Segments Covered Drug Type, Dosage Form, Distribution Channel And Region
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA)
Companies Mentioned AdvaCare Pharma, Akorn, Sun Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Rockwell Medical, Inc., Vifor Pharma Management Ltd., Shield Therapeutics, AMAG Pharmaceuticals.

COVID-19 Impact Assessment on Market Landscape

The report comprises the scrutiny of COVID-19 lock-down impact on the income of market leaders, disrupters and followers. Since lock down was instigated differently in diverse regions and nations, influence of same is also dissimilar across various industry verticals. The research report offers present short-term and long-term influence on the market to assist market participants across value chain makers to formulate the framework for short term and long-lasting tactics for recovery and by region.

Iron Deficiency Anemia Treatment market Report empowers readers with all-inclusive market intelligence and offers a granular outline of the market they are operational in. Further this research study delivers exceptional combination of tangible perceptions and qualitative scrutiny to aid companies accomplishes sustainable growth. This report employs industry-leading research practices and tools to assemble all-inclusive market studies, intermingled with pertinent data. Additionally, this report also emphases on the competitive examination of crucial players by analyzing their product portfolio, pricing, gross margins, financial position, growth approaches, and regional occurrence.

Iron Deficiency Anemia Treatment Market: Key Segments

In terms of drug type, the global iron deficiency anemia treatment market has been classified into ferrous sulfate, ferrous gluconate, ferrous fumerate, ferric hydroxide, sodium ferric gluconate, iron carbohydrates, and others

Based on dosage form, the global iron deficiency anemia treatment market has been categorized into tablets, capsules, and liquid. The tablets segment dominated the global market in 2020, owing to higher stability of tablets compared to other dosage forms, low manufacturing cost, and higher acceptability by patients.

In terms of distribution channel, the global iron deficiency anemia treatment market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is expected to expand at a high CAGR from 2020 to 2027. Benefits such as convenience, discounted products, large number of options, and detailed product description offered by the online pharmacies are likely to drive the segment during the forecast period.

North America to Dominate Global Market; Asia Pacific to Offer Significant Opportunities analysis:

In terms of region, the global iron deficiency anemia treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is projected to account for a leading share of the global iron deficiency anemia treatment market during the forecast period. Rise in prevalence of chronic kidney diseases and increase in patient base of iron deficient women in North America leading to a surge in demand for iron deficiency anemia treatment are major factors driving the market in the region. According to the CDC, in 2020, 15% of the U.S. adults i.e., 37 million people are anticipated to have had chronic kidney disease. Moreover, 15% women are suffering from CKD compared to 12% men. Furthermore, it is more common in people aged 65 years or older in the country. The market in Europe is expected to expand at a high CAGR in the near future, owing to the presence of local as well as global players and rise in demand for iron deficiency anemia treatment in the region.

The iron deficiency anemia treatment market in Asia Pacific is likely to grow at a rapid pace in the near future. India and China are anticipated to be lucrative markets for iron deficiency anemia treatment during the forecast period. Presence of large geriatric patient population with iron deficiency and increase in healthcare expenditure in these countries are projected to propel the market in Asia Pacific over the next few years.

Competitive Rivalry

Foremost players in the market are attentive on adopting corporation strategies to enhance their market share. Some of the prominent tactics undertaken by leading market participants in order to sustain the fierce market completion include collaborations, acquisitions, substantial spending in R&D and the improvement of new-fangled products or reforms among others.

Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.

  • Company Overview
  • Company Market Share/Positioning Analysis
  • Product Offerings
  • Financial Performance
  • Recent Initiatives
  • Key Strategies Adopted by Players
  • Vendor Landscape
  • List of Suppliers
  • List of Buyers

Some of the prominent players in the Iron Deficiency Anemia Treatment Market include: AdvaCare Pharma, Akorn, Sun Pharmaceutical Industries Ltd., Akebia Therapeutics, Inc., Rockwell Medical, Inc., Vifor Pharma Management Ltd., Shield Therapeutics, AMAG Pharmaceuticals.

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

Global Iron Deficiency Anemia Treatment Market: Segmentation

  • Iron Deficiency Anemia Treatment Market, by Drug Type
    • Ferrous Sulfate
    • Ferrous Gluconate
    • Ferrous Fumerate
    • Ferric Hydroxide
    • Sodium Ferric Gluconate
    • Iron Carbohydrates
    • Others
  • Iron Deficiency Anemia Treatment Market, by Dosage Form
    • Tablets
    • Capsules
    • Liquid
  • Iron Deficiency Anemia Treatment Market, by Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

By Geography

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Highlights of the Report:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the market.
  • Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the market

Research Methodology

In the study, a unique research methodology is utilized to conduct extensive research on the growth of the Iron Deficiency Anemia Treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the Iron Deficiency Anemia Treatment market study are as follows - statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, all of whom have contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the market, and makes the projections on the growth prospects of the Iron Deficiency Anemia Treatment markets more accurate and reliable.

Secondary Research

It involves company databases such as Hoover's: This assists us recognize financial information, structure of the market participants and industry competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire based research etc.
  • In order to validate our research findings and analysis we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

Industry participants involved in this research study include:

  • CEOs, VPs, market intelligence managers
  • Procuring and national sales managers technical personnel, distributors and resellers
  • Research analysts and key opinion leaders from various domains

Key Points Covered in Iron Deficiency Anemia Treatment market Study:

  • Growth of Iron Deficiency Anemia Treatment in 2021
  • Market Estimates and Forecasts (2017-2027)
  •  Brand Share and Market Share Analysis
  •  Key Drivers and Restraints Shaping Market Growth
  •  Segment-wise, Country-wise, and Region-wise Analysis
  •  Competition Mapping and Benchmarking
  •  Recommendation on Key Winning Strategies
  •  COVID-19 Impact on Demand for Iron Deficiency Anemia Treatment and How to Navigate
  •  Key Product Innovations and Regulatory Climate
  •  Iron Deficiency Anemia Treatment Consumption Analysis
  •  Iron Deficiency Anemia Treatment Production Analysis
  •  Iron Deficiency Anemia Treatment and Management

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Iron Deficiency Anemia Treatment Market, By Drug Type

7.1.  Iron Deficiency Anemia Treatment Market, by Drug Type, 2021-2027

7.1.1.     Ferrous Sulfate

7.1.1.1.          Market Revenue and Forecast (2016-2027)

7.1.2.     Ferrous Gluconate

7.1.2.1.          Market Revenue and Forecast (2016-2027)

7.1.3.     Ferrous Fumerate

7.1.3.1.          Market Revenue and Forecast (2016-2027)

7.1.4.     Ferric Hydroxide

7.1.4.1.          Market Revenue and Forecast (2016-2027)

7.1.5.     Ferric Hydroxide

7.1.5.1.          Market Revenue and Forecast (2016-2027)

7.1.6.     Sodium Ferric Gluconate

7.1.6.1.          Market Revenue and Forecast (2016-2027)

7.1.7.     Iron Carbohydrates

7.1.7.1.          Market Revenue and Forecast (2016-2027)

7.1.8.     Others

7.1.8.1.          Market Revenue and Forecast (2016-2027)

Chapter 8.    Global Iron Deficiency Anemia Treatment Market, By Dosage Form

8.1.  Iron Deficiency Anemia Treatment Market, by Dosage Form, 2021-2027

8.1.1.     Tablets

8.1.1.1.          Market Revenue and Forecast (2016-2027)

8.1.2.     Tablets

8.1.2.1.          Market Revenue and Forecast (2016-2027)

8.1.3.     Liquid

8.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 9.    Global Iron Deficiency Anemia Treatment Market, By Distribution Channel

9.1.  Iron Deficiency Anemia Treatment Market, by Distribution Channel, 2021-2027

9.1.1.     Hospital Pharmacies

9.1.1.1.          Market Revenue and Forecast (2016-2027)

9.1.2.     Retail Pharmacies

9.1.2.1.          Market Revenue and Forecast (2016-2027)

9.1.3.     Online Pharmacies

9.1.3.1.          Market Revenue and Forecast (2016-2027)

Chapter 10.Global Iron Deficiency Anemia Treatment  Market, Regional Estimates and Trend Forecast

10.1.          North America

10.1.1.  Market Revenue and Forecast, by Drug Type (2016-2027)

10.1.2.  Market Revenue and Forecast, by Dosage Form (2016-2027)

10.1.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.1.4.  U.S.

10.1.4.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.1.4.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.1.4.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.1.5.  Rest of North America

10.1.5.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.1.5.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.1.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.          Europe

10.2.1.  Market Revenue and Forecast, by Drug Type (2016-2027)

10.2.2.  Market Revenue and Forecast, by Dosage Form (2016-2027)

10.2.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.4.  UK

10.2.4.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.2.4.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.2.4.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.5.  Germany

10.2.5.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.2.5.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.2.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.6.  France

10.2.6.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.2.6.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.2.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.2.7.  Rest of Europe

10.2.7.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.2.7.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.2.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.          APAC

10.3.1.  Market Revenue and Forecast, by Drug Type (2016-2027)

10.3.2.  Market Revenue and Forecast, by Dosage Form (2016-2027)

10.3.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.4.  India

10.3.4.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.3.4.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.3.4.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.5.  China

10.3.5.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.3.5.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.3.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.6.  Japan

10.3.6.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.3.6.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.3.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.3.7.  Rest of APAC

10.3.7.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.3.7.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.3.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.          MEA

10.4.1.  Market Revenue and Forecast, by Drug Type (2016-2027)

10.4.2.  Market Revenue and Forecast, by Dosage Form (2016-2027)

10.4.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.4.  GCC

10.4.4.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.4.4.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.4.4.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.5.  North Africa

10.4.5.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.4.5.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.4.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.6.  South Africa

10.4.6.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.4.6.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.4.6.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.4.7.  Rest of MEA

10.4.7.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.4.7.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.4.7.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.          Latin America

10.5.1.  Market Revenue and Forecast, by Drug Type (2016-2027)

10.5.2.  Market Revenue and Forecast, by Dosage Form (2016-2027)

10.5.3.  Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.4.  Brazil

10.5.4.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.5.4.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.5.4.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

10.5.5.  Rest of LATAM

10.5.5.1.       Market Revenue and Forecast, by Drug Type (2016-2027)

10.5.5.2.       Market Revenue and Forecast, by Dosage Form (2016-2027)

10.5.5.3.       Market Revenue and Forecast, by Distribution Channel (2016-2027)

Chapter 11.   Company Profiles

11.1.                 AdvaCare Pharma

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.                  Akorn, Sun Pharmaceutical Industries Ltd

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.                 Akebia Therapeutics, Inc

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.                 Vifor Pharma Management Ltd

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.                  Shield Therapeutics

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.                  AMAG Pharmaceuticals

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

Chapter 12.   Research Methodology

12.1.                 Primary Research

12.2.                 Secondary Research

12.3.                 Assumptions

Chapter 13.   Appendix

13.1.                 About Us

13.2.                 Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers